Can we rely on one laboratory test in detection of extended-spectrum β-lactamases among Enterobacteriaceae? An evaluation of the Vitek 2 system and comparison with four other detection methods in Kuwait

Journal of Clinical Pathology

Volumn 62, Issue 8, 2009, Pages 739-742

  Dashti, A A ^a   Jadaon, M M ^a   Habeeb, F M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE;

ARTICLE; BACTERIAL INFECTION; BACTERIUM DETECTION; BACTERIUM ISOLATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EVALUATION RESEARCH; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; KUWAIT; LABORATORY TEST; MEDICAL PRACTICE; NONHUMAN; PRIORITY JOURNAL; RELIABILITY;

BACTERIOLOGICAL TECHNIQUES; BETA-LACTAMASES; DISK DIFFUSION ANTIMICROBIAL TESTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; REAGENT STRIPS; REPRODUCIBILITY OF RESULTS;

EID: 68149180908     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.066134     Document Type: Article

References (23)

1. Kliebe C, Nies BA, Meyer JF, et al. Evolution of plasmid-coded resistance to broadspectrum cephalosporins. Antimicrob Agents Chemother 1985;28:302-307 (Pubitemid 15019966)
2. Sanders CC, Barry AL, Washington JA, et al. Detection of extended-spectrum blactamase- producing members of the family Enterobacteriaceae with the Vitek ESBL test. J Clin Microbiol 1996;34:2997-3001.
3. Bradford PA. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951
4. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-1089 (Pubitemid 32299644)
5. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352:380-391
6. Livermore DM. b-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev1995;8:557-584
7. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686
8. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006;42:S153-63.
9. Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47:273-295 (Pubitemid 37322047)
10. Hawkey PM, Munday CJ. Multiple resistances in Gram-negative bacteria. Rev Medic Microbiol 2004;15:51-61.
11. Bradford PA, Urban C, Jaiswal A, et al. SHV-7, a novel cefotaxime-hydrolyzing blactamase identified in E.coli isolated from hospitalized nursing home patients. Antimicrob Agents Chemother 1995;39:899-905.
12. Gibb AP, Crichton M. Cefpodoxime screening of Escherichia coli and Klebsiella spp. by Vitek for detection of organisms producing extended-spectrum b-lactamases. Diag Microbiol Infect Dis 2000;38:255-257 (Pubitemid 32056231)
13. CLSI. Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document 2006;M100-S16. Wayne, PA: CLSI, 2006.
14. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-4581 (Pubitemid 39577656)
15. Dashti AA, West P, Paton R, et al. Characterization of extended-spectrum betalactamase (ESBL)-producing Kuwait and UK strains identified by the Vitek system, and subsequent comparison of the Vitek system with other commercial ESBL-testing systems using these strains. J Med Microbiol 2006;55:417-421
16. Appleton A, Hall S. Comparison of three combination discs for the detection of extended spectrum β-lactamases. The 3rd European Congress of Chemotherapy, Madrid, Spain, 7-10 May 2000.
17. Komatsu M, Aihara M, Shimakawa K, et al. Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae-producing, extended-spectrum betalactamases isolated in Japan. Diagn Microbiol Infect Dis 2003;46:125-130 (Pubitemid 36703349)
18. Leverstein-van Hall MA, Fluit AC, Paauw A, et al. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. J Clin Microbiol 2002;40:3703-3711
19. Linscott AJ, Brown WJ. Evaluation of four commercially available extendedspectrum beta-lactamase phenotypic confirmation tests. J Clin Microbiol 2005;43:1081-1085
20. Sanguinetti M, Posteraro B, Spanu T, et al. Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method. J Clin Microbiol 2003;41:1463-1468 (Pubitemid 36428090)
21. Schwaber MJ, Navon-Venezia S, Chmelnitsky I, et al. Utility of the VITEK 2 advanced expert system for identification of extended-spectrum beta-lactamase production in Enterobacter spp. J Clin Microbiol 2006;44:241-243 (Pubitemid 43100612)
22. M'Zali FH, Chanawong A, Kerr KG, et al. Detection of extended-spectrum b-lactamases in members of the family Enterobacteriaceae. Comparison of the MAST DD test, the double disc and the Etest ESBL. J Antimicrob Chemother 2000;45:881-885 (Pubitemid 30348961)
23. Crowley DB. Extended-spectrum b-lactamases in blood culture isolates of Klebsiella pneumoniae: seek and you may find! J Antimicrob Chemother 2001;47:728-737